FdaApplication
BLA 021273
Identifiers
- fda_app_no: BLA021273
Properties
| Property | Value |
|---|---|
| applicant_name | Organon USA Inc., a subsidiary of Merck & Co., Inc. |
| application_type | BLA |
| approval_date | 2005-08-26 |
Revenue by product
FOLLISTIM AQ
| Period | Revenue |
|---|---|
| Q2 2026 | $59.0M |
| Q1 2026 | $61.0M |
| Q4 2025 | $58.0M |
| Q3 2025 | $64.0M |
| Q2 2025 | $74.0M |
| Q1 2025 | $69.0M |
| Q4 2024 | $66.0M |
| Q3 2024 | $63.0M |
| Q2 2024 | $62.0M |
| Q1 2024 | $46.0M |
| Q4 2023 | $83.0M |
| Q3 2023 | $54.0M |
| Q2 2023 | $70.0M |
| Q1 2023 | $55.0M |
| Q4 2022 | $50.0M |
| Q3 2022 | $60.0M |
| Q1 2021 | $52.0M |
| Q4 2020 | $57.0M |
| Q3 2020 | $50.0M |
| Q2 2020 | $44.0M |
| Q1 2020 | $41.0M |
| Q4 2019 | $59.0M |
| Q3 2019 | $62.0M |
| Q2 2019 | $63.0M |
| Q1 2019 | $57.0M |
| Q4 2018 | $70.0M |
| Q3 2018 | $60.0M |
| Q2 2018 | $70.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| FOLLISTIM AQ | FOLLITROPIN ALFA/BETA | 150IU/0.5ML | Injection |
| FOLLISTIM AQ | FOLLITROPIN ALFA/BETA | 75IU/0.5ML | Injection |
2 products